- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03278704
Concurrent Training in Type 2 Diabetes (CONTRADIA)
Effects of Concurrent Resistance Exercise and High-intensity Interval Exercise Training on Skeletal Muscle Adaptations in Individuals With Type 2 Diabetes Mellitus
It is recommended that individuals perform a combination of resistance exercise (RE) and endurance exercise. Lack of time is often cited as a reason for being unable to meet current exercise guidelines. Therefore, combining both forms in one session may be beneficial. However, research continues to elucidate whether interference of adaptive outcomes occurs when RE and endurance exercise are performed concurrently. A proposed interference effect suggests that concurrent training may dampen RE-induced adaptations (e.g., muscle strength and growth) compared to RE only.
The propose of this investigation is to determine the effects of concurrent RE and high-intensity interval training (HIIT), compared to RE only, on muscle health and cardiovascular risk in sedentary, middle-aged (40-65 years) who are overweight/obese with type 2 diabetes mellitus (T2DM). The investigators will measure the effects on muscle strength, muscle growth, cardiovascular fitness, glycaemic control and markers of cardiovascular risk before and after an 8-week training program. Data will be obtained through the analysis of skeletal muscle samples, blood samples, magnetic resonance imaging, questionnaires and exercise performance tests.It is hypothesized that concurrent RE + HIIT will amplify the exercise-induced muscle growth response, which will result in greater satellite cell content, compared to RE alone. As a result, this will lead to greater skeletal muscle mass and strength after RE + HIIT compared to RE in isolation.
A finding that concurrent resistance training and HIIT does not impede muscle adaptations could offer future strategies to minimize exercise time commitment whilst still maximizing the physiological benefits of both resistance and endurance exercise through a single training session. This may therefore provide an effective exercise strategy in the prevention and/or treatment of T2DM.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Data analysis will be performed using IBM SPSS statistical software (IBM Corp., Armonk, New York, USA). All data will be checked for normality and appropriate log transformations applied prior to analysis of variance (ANOVA) for primary and secondary outcomes. Satellite cell content will be compared using a two-way, mixed-model ANOVA with one within (2 levels; pre- and post-training) and one between factor (2 level; exercise group) with significance set at P < 0.05.
Based on a mixed ANOVA with between- and within-participant factors, and previously published data (Babcock et al. 2012), a sample size of 24 participants (12 per group) will provide a power of 84%. This sample size will allow detection of a mean change in satellite cell content of 2.35, assuming standard deviations of the change from pre- to post-training as 2.266 and 1.331 in the two exercise groups. Sample size calculation was performed with an alpha error of 0.05. SamplePower 2.0 (SPSS Inc., Chicago, Illinois, USA) software was used to determine sample size.
This study will combine data collected at the University of Birmingham with previously collected data from an identical study design performed by a co-investigator (Dr Pugh) in Rome, Italy. The previous study has collected data from 10 participants across both exercise groups (RE, N = 7; RE + HIIT, N = 3). Therefore, it is necessary for the present study to recruit a further 14 participants (RE, N = 5, RE + HIIT, N = 9) in order to achieve a sample size of 24 participants (12 per group). However, based on an assumption of a 25% drop-out rate, the total minimal sample necessary will be 19 participants (RE, N = 7; RE + HIIT, N = 12).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Birmingham, United Kingdom, B15 2TT
- School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male sex
- White British/European
- Aged between 40 and 65 years at the time of screening
- Have a body mass index (BMI; body weight/height in m2) between 27 and 40 kg/m2
- Sedentary/untrained for at least 1 year (based on physical activity self-reports of fewer than two sessions of structured exercise per week last <30 min)
- T2DM (American Diabetes Association 2014) for more than 1 year
- Central obesity (defined as waist circumference ≥94 cm for males)
Exclusion Criteria:
- Currently involved in research or have recently (<6 months) been involved in any research prior to recruitment
- Any condition limiting or contraindicating physical activity; including diabetic peripheral neuropathy, and coronary or peripheral artery disease
- Previous myocardial infarction, previous or current angina, shortness of breath, or other symptoms suggestive of heart failure
- Insulin medication
- HbA1c more than 75 mmol/mol (9%)
- Uncontrollable hypertension: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg
- Not weight stable for the last three months
- Smokers (within the last 12 months)
- Anticoagulant medication, such as warfarin or newer anticoagulant drugs. If participants are on aspirin medication, this would need to be stopped for 3 days prior to and during the day of any biopsy visit unless contraindicated (in which case participants would be excluded).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: RE training only
RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
|
8 weeks of supervised training.
Three times weekly with no more than two non-consecutive days without exercise.
|
|
Experimental: Concurrent RE + HIIT
RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
|
8 weeks of supervised training.
Three times weekly with no more than two non-consecutive days without exercise.
Concurrent training: RE followed by HIIT within the same session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in fibre-type specific satellite cell content
Time Frame: Prior to the 8-week training intervention and 72 hours after the last training session
|
Assessed using immunofluorescence microscopy (Pax7-positive cells)
|
Prior to the 8-week training intervention and 72 hours after the last training session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in muscle-specific gene expression related to growth adaptations
Time Frame: Prior to the 8-week training intervention and 72 hours after the last training session
|
Assessed using reverse-transcription polymerase chain reactions
|
Prior to the 8-week training intervention and 72 hours after the last training session
|
|
Change in muscle fibre size
Time Frame: Prior to the 8-week training intervention and 72 hours after the last training session
|
Assessed using immunofluorescence microscopy techniques to determine muscle fibre type-specific cross-sectional area
|
Prior to the 8-week training intervention and 72 hours after the last training session
|
|
Change in muscle size
Time Frame: Prior to the 8-week training intervention and 48 hours after the last training session
|
Assessed using MRI to determine whole and individual muscle group cross-section area and total muscle volume
|
Prior to the 8-week training intervention and 48 hours after the last training session
|
|
Change in isometric muscle strength
Time Frame: Prior to the 8-week training intervention and 6 days after the last training session
|
Assessed using a dynamometer
|
Prior to the 8-week training intervention and 6 days after the last training session
|
|
Change in isokinetic muscle strength
Time Frame: Prior to the 8-week training intervention and 6 days after the last training session
|
Assessed using a dynamometer
|
Prior to the 8-week training intervention and 6 days after the last training session
|
|
Change in cardiorespiratory fitness
Time Frame: Prior to the 8-week training intervention and 6 days after the last training session
|
Assessed using a V̇O2 peak test on a cycle ergometer
|
Prior to the 8-week training intervention and 6 days after the last training session
|
|
Change in habitual physical activity levels
Time Frame: Prior to the 8-week training intervention and 1 week after the last training session
|
Assessed using 7-day continuous accelerometry data
|
Prior to the 8-week training intervention and 1 week after the last training session
|
|
Change in exercise enjoyment
Time Frame: After the first and last training session
|
Assessed using validated questionnaires (PACES)
|
After the first and last training session
|
|
Change in glycaemic control
Time Frame: Prior to the 8-week training intervention and 72 hours after the last training session
|
Assessed using blood analysis
|
Prior to the 8-week training intervention and 72 hours after the last training session
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Professor M Nimmo, PhD, University of Birmingham
Publications and helpful links
General Publications
- American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014 Jan;37 Suppl 1:S14-80. doi: 10.2337/dc14-S014. No abstract available.
- Babcock L, Escano M, D'Lugos A, Todd K, Murach K, Luden N. Concurrent aerobic exercise interferes with the satellite cell response to acute resistance exercise. Am J Physiol Regul Integr Comp Physiol. 2012 Jun 15;302(12):R1458-65. doi: 10.1152/ajpregu.00035.2012. Epub 2012 Apr 4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RG_16-218
- ERN_16-1612 (Other Identifier: University of Birmingham ethics number)
- RRK6071 (Other Identifier: NHS R&D reference number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
Clinical Trials on RE only
-
University of Alabama at BirminghamCompleted
-
Asklepios proresearchAsklepios Klinik St. GeorgCompleted
-
Ege UniversityNot yet recruiting
-
Nantes University HospitalCompleted
-
Marieke GoodijkDutch Cancer SocietyRecruiting
-
University Hospital HeidelbergRecruitingLocally Advanced Head-and-Neck CancerGermany
-
Sun Yat-sen UniversityRecruitingRecurrent Nasopharynx Carcinoma | Nasopharangeal CancerChina
-
Université de SherbrookeRecruitingBlood Pressure | Blood Pressure Monitoring, Ambulatory | Blood Pressure, High | Blood Pressure ManagementCanada
-
University of Alabama at BirminghamTerminatedRecurrent Malignant Glioma | Glioblastoma Multiforme of Brain | Anaplastic Astrocytoma of Brain | Gliosarcoma of BrainUnited States
-
Bayside HealthCompletedUnstable Cervical InjuryAustralia